SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients

Autor: Naif A.M. Almontashiri, Rowa Y. Alhabbab, M-Z Aki ElAssouli, Turki S. Abujamel, Reem M. Alsulaiman, Rahaf H. Alharbi, Asim Khogeer, Sawsan S. Al-amri, Ahmad Bakur Mahmoud, Almohanad A. Alkayyal, Ahdab AlSaieedi, Haya I. Hobani, Anwar M. Hashem, Mohamed A. Alfaleh, Sarah A Almahboub, Afrah Alsomali, Abdullah Algaissi, Fadwa S. Alofi, Wesam H. Abdulaal, Sharif Hala, Arnab Pain, Khalid A Alluhaybi
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
viruses
lcsh:Medicine
medicine.disease_cause
Antibodies
Viral
Immunoglobulin G
Serology
Cohort Studies
0302 clinical medicine
Medicine
030212 general & internal medicine
lcsh:Science
Multidisciplinary
biology
Middle Aged
Nucleocapsid Proteins
Seroconversion
Spike Glycoprotein
Coronavirus
Middle East Respiratory Syndrome Coronavirus
Female
Antibody
Coronavirus Infections
Infection
Adult
Coronavirus disease 2019 (COVID-19)
Middle East respiratory syndrome coronavirus
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pneumonia
Viral
Enzyme-Linked Immunosorbent Assay
Cross Reactions
Real-Time Polymerase Chain Reaction
Sensitivity and Specificity
Virus
Article
medicine_pharmacology_other
03 medical and health sciences
Betacoronavirus
Young Adult
Coronavirus Nucleocapsid Proteins
Humans
Serologic Tests
Pandemics
Aged
business.industry
SARS-CoV-2
lcsh:R
COVID-19
biology.organism_classification
Phosphoproteins
Virology
030104 developmental biology
Antibody response
Immunoglobulin M
Viral infection
biology.protein
lcsh:Q
business
Zdroj: Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
ISSN: 2045-2322
Popis: As the Coronavirus Disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world, there is a need for well validated serological assays that allow the detection of viral specific antibody responses in COVID-19 patients or recovered individuals. In this study, we established and used multiple indirect Enzyme Linked Immunosorbent Assay (ELISA)-based serological assays to study the antibody response in COVID-19 patients. In order to validate the assays we determined the cut off values, sensitivity and specificity of the assays using sera collected from pre-pandemic healthy controls, COVID-19 patients at different time points after disease-onset, and seropositive sera to other human coronaviruses (CoVs). The developed SARS-CoV-2 S1 subunit of the spike glycoprotein and nucleocapsid (N)-based ELISAs not only showed high specificity and sensitivity but also did not show any cross-reactivity with other CoVs. We also show that all RT-PCR confirmed COVID-19 patients tested in our study developed both virus specific IgM and IgG antibodies as early as week one after disease onset. Our data also suggest that the inclusion of both S1 and N in serological testing would capture as many potential SARS-CoV-2 positive cases as possible than using any of them alone. This is specifically important for tracing contacts and cases and conducting large-scale epidemiological studies to understand the true extent of virus spread in populations.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje